The current literature presents limited and inconsistent results regarding the influence of PgR levels on survival outcomes in patients with HR-positive/HER2-negative metastatic BC treated with CDK 4/6 inhibitors [19,20,21,22,23]. This evidence concerns the gene ERBB2 and breast cancer.